MDACC Study No:2013-0319 ( NCT No: NCT01796470)
Title:A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination with Idelalisib in Subjects with Relapsed or Refractory Hematologic Malignancies
Principal Investigator:William G. Wierda
Treatment Agent:GS-1101
Study Status:Closed
Study Description:The initial goal of this clinical research study was to learn if GS-9973 in
combination with idelalisib can help to control CLL. The safety of these drugs
was also studied.

Due to a serious safety concern of inflammation of the lungs, this combination
treatment has been stopped. The increased risk of lung problems has not been
seen with GS-9973 alone.

If you and your Study Doctor have decided that you should continue in the study
you will be receiving only GS-9973.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:GS-1101
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Gilead Sciences, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-792-7543
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults